A Study of TY-1091 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown 248 enrolled TYK Medicines, Inc

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

Timeline

Start: 2023-04-24
Primary completion: 2025-06-01
Completion: 2025-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TY-1091	Unknown	10 mg	Oral
Subject	TY-1091	Unknown	100 mg	Oral

A Study of TY-1091 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications